Precision management of brain oedema after acute ischaemic stroke

Simiao Wu1,2 and Craig S Anderson3,4,*

1Department of Neurology, West China Hospital, Sichuan University, Chengdu 610041, China
2Centre for Cerebrovascular Diseases, West China Hospital, Sichuan University, Chengdu 610041, China
3The George Institute for Global Health, Faculty of Medicine, University of New South Wales, Sydney NSW 2050, Australia
4The George Institute for Global Health China, Beijing 100600, China
*Correspondence to: Craig S Anderson, canderson@georgeinstitute.org.au

Dear Editor,

Stroke is a leading cause of death and disability in the world, with acute ischaemic stroke accounting for ~70% of all cases. Some degree of brain oedema occurs in all cases of acute ischaemic stroke and, when severe, has major consequences on survival-free of disability. Pathophysiological studies indicate an evolution of cytotoxic oedema, ionic oedema, and vasogenic oedema, which implies brain oedema is a dynamic process and explains the various terminology used, such as large hemispheric infarction, symptomatic infarct swelling, space-occupying infarction, or malignant middle cerebral artery (MCA) infarction. Heterogeneity in manifestations and sequelae necessitates a new, precision medicine approach to individualizing prevention and treatment of brain oedema after stroke.

Approximately 10% of patients with ischaemic stroke develop symptomatic brain swelling, most occurring within the first few days after symptom onset. Malignant MCA infarction is a fatal stage of brain oedema, with a rapid deterioration in neurological deficits associated with brain oedema, which can evolve into a malignant course with massive brain swelling, transtentorial herniation, and death or disability. To interrupt such a malignant course, current guidelines recommend that patients aged between 18 and 60 years who develop space-occupying hemispheric infarction within 48 hours, would benefit from decompressive hemicraniectomy (DHC). Randomized controlled trials have shown that DHC reduces the risk of fatal brain oedema, albeit in selected patients and with some offset price from persistent disability in survivors; however, there is insufficient evidence to inform the appropriate management of patients who present after 48 hours. More data are needed to determine the benefits and risks of DHC in broader patient groups. Ongoing observational studies will allow greater clarity over clinical and imaging predictors, and of the natural history of malignant brain oedema (e.g. NCT03222024), to inform patient selection and optimal therapeutic windows for the design of interventions studies.

Early identification of patients at a high-risk of developing malignant brain oedema would guide timely interventions and improve outcome prediction. A recent systematic review and meta-analysis included 38 studies involving 3278 patients and analysed 24 clinical factors, seven domains of imaging markers, and 13 serum biomarkers for predicting malignant brain oedema. Overall, a younger age, more severe neurological deficits, larger infarct volume, and early signs of brain oedema are the reliable early predictors for malignant brain oedema, while successful revascularization is associated with a reduced risk (Table 1). The effect of revascularization on reducing the risk of malignant brain oedema has been further clarified in reperfusion trials. These findings provide mechanistic insights to underpin the benefit of reperfusion treatment, even in patients with large infarction, and imply that proper management of brain oedema may further improve outcomes in patients with very large infarction.

The development of brain oedema after stroke is associated with the damage to the blood–brain barrier. Simard et al. found a sulfonylurea receptor 1 (SUR1)-regulated NCCATc channel was involved in the development of brain oedema in rodent stroke models. Moreover, gliobenclamid (an SUR1 inhibitor) has been shown to reduce the volume of infarction and swelling in rodent stroke models. There is a phase II clinical trial which showed intravenous gliobenclamid reduced midline shift, and reduced death from brain oedema in patients with large hemispheric infarction (NCT01794182). A subsequent phase III trial is ongoing (NCT02864953). Neuroinflammation is another possible mechanism for brain oedema. Animal studies show that NOD-like receptor thermal protein domain associated protein 3 (NLRP3) is up-regulated in ischaemic brain tissue, aggregates neuroinflammation, and is associated with neurovascular damage after stroke. A clinical study found that serum concentration of NLRP3, assessed within 24 hours after stroke (median time from onset to blood collection, 3 hours) was higher in patients who developed malignant brain oedema at a later stage than those without malignant brain oedema (1.85 vs. 1.11 ng/ml; = 0.026); furthermore, NLRP3 level was positively correlated with neurological impairment (on the National Institutes of Stroke Scale [NIHSS]) score on admission (Spearman = 0.18, = 0.01), and the association between NLRP3 and brain oedema was attenuated (OR 1.47, 95% CI 0.88–2.46; = 0.138) after adjustment for age and NIHSS score. These findings indicate a role for neuroinflammation and increased microvascular permeability in the development of malignant brain oedema. Identification of more novel biomarkers could...
Table 1. Factors for prediction and prevention for malignant brain oedema after stroke.

| Factors for prediction | Characteristics and treatment effect on malignant brain oedema |
|------------------------|---------------------------------------------------------------|
| **Clinical features**  | 22 studies, 2075 patients, pooled MD = -4.42, 95% CI = -6.63 to -2.22 |
| Age (years)            | 8 studies, 807 patients, range of median score 17 to 20 vs. 5 to 15 |
| Depressed consciousness| 6 studies, 573 patients, pooled OR 6.65, 95% CI 3.38 to 13.46 |
| **Imaging signs**      | 13 studies, 929 patients, pooled SMD 2.57, 95% CI 1.82 to 3.31 |
| Infarct volume (cm³)   | 4 studies, 420 patients, pooled OR 5.33, 95% CI 2.93 to 9.68 |
| Hypoattenuation >50% of MCA territory | 5 studies, 526 patients, pooled OR 7.75, 95% CI 2.40 to 25.04 |
| Midline shift          | 3 studies, 199 patients, pooled OR 13.90, 95% CI 3.13 to 61.82 |
| Compression of ventricles| 2 studies, 284 patients, pooled OR 19.09, 95% CI 5.00 to 72.93 |
| BBB permeability†      | 1 study, 238 patients, common OR 1.12, 95% CI 1.03 to 1.20, P = 0.005 |
| Cerebral blood flow†    | 1 study, 238 patients, common OR 0.25, 95% CI 0.10 to 0.58, P = 0.001 |
| Revascularization status| 13 studies, 1600 patients, pooled OR 0.37, 95% CI 0.24 to 0.57 |
| **Serum biomarkers**   | 2 studies, 113 patients, pooled SMD 1.06, 95% CI 0.64 to 1.48 |
| S100B (µg/l)           | 1 study, 200 patients, median value 1.85 vs. 1.11, P = 0.03 |
| NLRP3 (ng/ml)          | 1 study, 1039 patients, adjusted OR 1.421, 95% CI 1.164 to 1.735, P = 0.001 |
| **Reperfusion interventions for prevention** | 1 study, 2961 patients: intravenous alteplase was associated with an increased risk of malignant brain oedema, but it was also associated with accelerated clearance of hypertense artery sign on brain CT (OR 0.67, 95% CI 0.50–0.91), which in return reduced brain swelling (OR 0.25, 95% CI 0.14–0.47) |
| IST-3 Collaborative Group | 1 study 462 patients: successful endovascular after reperfusion intervention was associated with reduced middle shift (OR 0.25, 95% CI 0.12–0.53) |
| MR CLEAN Investigators | 7 studies, 177 patients with large hemorrhagic infarction*: thrombectomy and reperfusion were both associated with functional improvement (common OR 2.30, 95% CI 1.32–4.00 for thrombectomy, common OR 4.73, 95% CI 1.66–13.52 for reperfusion) but not of the degree of midline shift (p = 0.27, 95% CI 1.52 to 0.98, perfusion β = −0.78, 95% CI −3.07 to 1.50); in 76 patients with very large infarction**: thrombectomy was associated with greater midline shift (β 2.76, 95% CI 0.33–5.20) but not functional improvement (OR 1.71, 95% CI 0.24–12.08) |
| HERMES Collaborators   | 7 studies, 13 patients, pooled OR 0.98; reperfusion β = 0.001; 95% CI 0.24–12.08) |

Note: ASPECTS: Alberta Stroke Program Early CT Score; BBB: blood–brain barrier; CI: confidence interval; CT: computed tomography; CTP: computerized tomographic perfusion; DWI: diffusion weighted imaging; HERMES: the Highly Effective Reperfusion evaluated in Multiple Endovascular Stroke Trials; IST-3: The third International Stroke Trial; MCA: middle cerebral artery; MD: mean difference; NIHSS: National Institute of Health Stroke Scale; NLRP3: nucleotide-binding oligomerization domain-like receptor family pyrin domain-containing 3; NT-proBNP: N-terminal probrain natriuretic peptide; OR: odds ratio; SMD: standardized mean difference.

---


table1

---

improve the accuracy of prediction and provide new targets for treatment.

In summary, brain oedema is a common complication of acute ischaemic stroke and an important preventable cause of death. Reperfusion therapies and DHC benefit selected high-risk patients. Further studies are needed to clarify natural history and mechanisms, with an aim to inform greater precision in outcome prediction at an early stage, guide timely interventions for prevention and treatment, broaden the benefit of existing effective therapies, and provide novel treatment targets.

Conflict of interest

None declared.

Acknowledgements

This work is supported by the National Natural Science Foundation of China (Grant No. 82171285), the Science & Technology Department of Sichuan Province (Grant No. 2021YJ0433), and the 1·3·5 Project for Disciplines of Excellence, West China Hospital, Sichuan University (Grant No. ZYGD18009). We are grateful to Dr. Meng Liu at West China Hospital, Sichuan University for her help with preparing data in Table 1.

References

1. Wu S, Wu B, Liu M, et al. Stroke in China: advances and challenges in epidemiology, prevention, and management. Lancet Neurol 2019;18:394–405. doi:10.1016/S1474-4422(18)30500-3.
2. Simard JM, Kent TA, Chen M, et al. Brain oedema in focal ischaemia: molecular pathophysiology and theoretical implications. Lancet Neurol 2007;6:258–68. doi:10.1016/S1474-4422(07)70055-8.
3. Huttner HB, Schwab S. Malignant middle cerebral artery infarction: clinical characteristics, treatment strategies, and future perspectives. Lancet Neurol 2009;8:949–58. doi:10.1016/S1474-4422(09)70224-8.
4. van der Worp HB, Hofmeijer J, Jüttler E, et al. European Stroke Organisation (ESO) guidelines on the management of space-occupying brain infarction. Eur Stroke J 2021;6(2):III. doi:10.1177/23969873211027001.
5. Wu S, Yuan R, Wang Y, et al. Early prediction of malignant brain edema after ischemic stroke: a systematic review and meta-analysis. Stroke 2018;49:2918–27. doi:10.1161/STROKEAHA.118.022001.
6. Simard JM, Chen M, Tarasov KV, et al. Newly expressed SUR1-regulated NC(Ca-ATP) channel mediates cerebral edema after ischemic stroke. Nat Med 2006;12:433–40. doi:10.1038/nm1390.
7. Simard JM, Tsymbalyuk N, Tsymbalyuk O, et al. Gilbenclamide is superior to decompressive craniectomy in...
8. Wang Y, Huang H, He W, et al. Association between serum NLRP3 and malignant brain edema in patients with acute ischemic stroke. BMC Neurol 2021;21:341. doi:10.1186/s12883-021-02369-4.

9. Ng FC, Churilov L, Yassi N, et al. Microvascular dysfunction in blood-brain barrier disruption and hypoperfusion within the infarct posttreatment are associated with cerebral edema. Stroke 2022;53(5):1597–1605. doi:10.1161/STROKEAHA.121.036104.

10. Zhang X, Yan S, Zhong W, et al. Early NT-proBNP (N-terminal probrain natriuretic peptide) elevation predicts malignant edema and death after reperfusion therapy in acute ischemic stroke patients. Stroke 2021;52(2):537–42. doi:10.1161/STROKEAHA.120.029593.